Hjem › Follikulært lymfom › North Carolina
Follikulært lymfom kliniske forsøg i North Carolina
23 studier for Follikulært lymfom søger deltagere på steder i North Carolina.
Byer i North Carolina
Officiel studietekst (engelsk)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Charlotte
- Research Site, Winston-Salem
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307), Durham
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07634471A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Charlotte
- Research Site, Wilmington
- Research Site, Winston-Salem
RekruttererFase 3
Alder 18 til 130 · Alle køn · Opdateret 21. sep. 2026 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Charlotte
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- University of North Carolina, Chapel Hill
- Levine Cancer Institute, Charlotte
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06091254A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
RekruttererObservationsstudie
Alder 0 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07154823Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Pain With Dementia
- Duke University Medical Center, Durham
RekruttererFrivillige med god helbredstilstand velkomne
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06854718A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 1. jul. 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- og 4 flere
RekruttererObservationsstudie
Alder 65 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT01137825Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT04775745Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT04223765AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RekruttererObservationsstudie
Alder 18 til 120 · Alle køn · Opdateret 27. okt. 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034Cognition, Flavonoids, Exercise, Gut Microbiome
- Appalachian State University Human Performance Lab, North Carolina Research Campus, Kannapolis
RekruttererFrivillige med god helbredstilstand velkomne
Alder 65 til 85 · Alle køn · Opdateret 12. mar. 2025 · NCT06495190Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.